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Abstract
Abrishami, Oortwijn, and Hofman (AOH) attribute to me a position I do not hold and an argument I did not 
make. The purpose of this note is make clear what my position actually is and to clarify the main differences 
between health technology assessment (HTA) and cost-effectiveness analysis (CEA).
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A Misattribution
While I find myself in agreement with a good deal of what 
they write (for example, that health technology assessment 
[HTA] should be user-centred and suitable for legitimising 
decisions), Abrishami, Oortwijn, and Hofman (henceforth 
AOH) attribute1 to me a position I do not hold and an 
argument I did not make.2 This commentary aims to clarify 
a misattribution made by AOH. In a discussion of the 
editorial by Daniels and colleagues3 they claim that I make 
an “underlying,” and therefore implicit, assumption to the 
effect that HTA has a pre-existing “framework” with specific 
disciplinary associations that is “widely agreed.” Apparently, 
my view is also that this framework has “boundaries.” It is the 
boundaries that define the possible need for “expansion” so as 
to include matters beyond them.
Is the Scope of an HTA Determined a Priori?
This is not my view and, in my opinion, is not a particularly 
helpful way of determining the scope of HTA. My view is that 
the proper scope of HTA is determined by the problem it is 
being harnessed to elucidate, which in turn is determined 
by the “ownership” of that problem (ie, the decision-makers 
in question) and the circumstances or context in which the 
decision is to be made. These circumstances include the 
country, its history and culture, the resources available, the 
political climate and the implementability of any actions 
decided upon after analysis. The choice being considered in 
an HTA is bounded only by considerations such as these. It 
follows that it is not necessary for the HTA analyst to agonise 
about the “need for expansion.” The range of considerations 
will be determined by the social values chosen by decision-
makers, or given to them by higher authorities.4,5 This range 
is contextual. The HTA analyst has the job of eliciting both 
the values to be respected in any analysis and judging the 
feasibility of various options, given the policy objectives of 
whomever is commissioning the work (typically a department 
of government or a senior manager in an insurance company). 
What is socially right and ethical is not, therefore, to be 
decided a priori but in the light of the specific context.
Many of the elements of an HTA are rich in terms of social 
value judgments: the budget available will depend upon 
priorities established between alternative uses for resources 
inside and outside healthcare; the measures of outcome (like 
lives saved, quality-adjusted life year and disability-adjusted life 
year) are deeply imbued with social values that give meaning 
to some concept of “health” and that may vary according to 
whose life is likely to be affected (like babies, children, adults, 
the elderly, the mentally ill, informal family carers, people 
with multiple morbidities); the likely consequences of a 
decision for the distribution of the burdens of sickness and 
of healthcare expenditures; the acceptability of degrees of risk 
under conditions of uncertainty. There are also other kinds 
of judgment that are often required: how good or complete 
the research evidence; what the balance should be between 
quantitative and qualitative evidence; how transferable the 
results obtained in one study in another are to the country in 
question; how competently the systematic reviews, research 
summaries and all other supporting analyses have been done; 
how acceptable the necessary changes are in affected persons’ 
political and financial interests; how willing the professional 
groups are who are essential to implementation.
In principle, any or all of these factors (or indeed others) 
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can be elements of an HTA. Whether in any specific context 
each or them is relevant depends on the context.
AOH advance the social value judgment that “the needs 
of the population must be the prime criteria.” This sounds 
innocuous enough but, since the very purpose of an HTA is 
to help decide what it is that is needed and by whom, it is 
circular and uninformative. Moreover, the interest may not be 
in the needs as such but in their distribution in a population 
or subgroup of a population. 
The very first task in any HTA is therefore to establish as 
precisely as one can what the question is.5 This normally entails 
identifying one or more interventions that can affect health 
for the better; settling what is meant by “health”; deciding 
the criteria for choosing between the interventions (cost-
effectiveness, equity, sustainability, religious proscriptions); 
various speeds of implementation; identifying potential gainers 
and losers; evaluating what other services will necessarily be 
forgone as a consequence of a decision to spend; making 
interpersonal comparisons between ethical claims to benefit; 
deciding who will be consulted and otherwise involved in the 
decision-making process6-8; identifying any training needs 
required for conducting the analysis and for implementing 
its results; and conveying the recommendations to “board 
level” authorities, clinical professionals, managers, organised 
patient groups and the general public.
Cost-effectiveness analysis (CEA) is a part of HTA but ought 
not to be identified with it. CEA does indeed have specific 
disciplinary roots (notably relevant clinical disciplines, 
economics, epidemiology and bio-statistics, and information 
science) and has a specific criterion (ie, cost-effectiveness). 
HTA is usually broader. It embraces cost-effectiveness of 
course, along with its associated disciplines, but often also 
requires the insights of ethics, theories of justice, management 
science, political science as well as others needed because of 
the specific nature of the interventions under consideration.
Need for Pragmatism
HTA can be a costly business. The scope and the procedures I 
have just described will not always be judged worthwhile. But 
whether the scope be broad and the procedures “legitimate,” 
or neither, is not determined by any “framework” or 
restrictive “framing.” Nor is it restricted to the practitioners of 
a conventional set of disciplines or professions. Regarding the 
former, the basic requirement is simply that an HTA address 
the issues considered to be significant by the decision-makers 
and their expert advisers. Regarding the latter, one requires 
only sufficient competence to deliver an analysis that meets 
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